Bionano Genomics (BNGO) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue was $7.8 million, a 10% year-over-year decrease, mainly due to discontinued clinical services and underperformance in China, while the OGM installed base grew 29% to 363 systems.

• Flowcell sales declined 13% year-over-year to 6,165 units, marking the first decline in 20 quarters, primarily due to China and transition effects in the Americas.

• Achieved a major milestone with the AMA's acceptance of a Category I CPT code for OGM in hematological malignancy analysis, expected to drive adoption and reimbursement.

• Implemented significant cost savings initiatives, including a headcount reduction of 120, targeting $65–$75 million in annualized non-GAAP expense reductions by Q1 2025.

• Net loss for Q2 2024 was $16.2 million, a 58% improvement from Q2 2023, driven by reduced R&D and SG&A expenses.

Financial highlights

• Q2 2024 revenue: $7.8 million, down 10% year-over-year; product revenue nearly flat, service revenue down 39%.

• GAAP gross margin improved to 33% from 27% in Q2 2023; non-GAAP gross margin rose to 35% from 29%.

• GAAP operating expense was $19.6 million, non-GAAP $18.8 million, both down over 46% year-over-year.

• Net loss for Q2 2024 was $16.2 million, compared to $38.9 million in Q2 2023.

• Cash, cash equivalents, and available-for-sale securities totaled $30.3 million as of June 30, 2024, with $11.4 million restricted.

Outlook and guidance

• Q3 2024 revenue expected between $7.9 million and $8.9 million.

• Full-year 2024 revenue guidance adjusted to $36 million–$40 million, down from $37 million–$41 million, due to China slowdown.

• Targeting an installed base of 381–401 OGM systems by year-end 2024.

• Full realization of $65–$75 million in annualized non-GAAP expense reductions expected by Q1 2025.

• Management expects continued operating losses and negative cash flows for at least the next year; additional capital needed beyond Q4 2024.